Maternal Use of Acetaminophen (Paracetamol) During Pregnancy and Neurodevelopmental Disorders in Offspring: A Reasoned Evaluation of Risk
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Gestational acetaminophen (paracetamol) use shows a small association with autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD), but sibling studies suggest shared factors, not the drug itself, explain the risk.
Area Of Science
- Neurodevelopmental Disorders
- Pregnancy Safety
- Pharmacovigilance
Background
- Gestational acetaminophen (paracetamol) use is common, yet its potential link to neurodevelopmental disorders (NDDs) like autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD) is debated.
- While large studies show associations between prenatal acetaminophen and NDDs, the observed risks are statistically small and potentially confounded.
Purpose Of The Study
- To critically examine the scientific evidence regarding gestational acetaminophen exposure and the risk of NDDs in children.
- To evaluate confounding factors, alternative explanations, and implications for clinical decision-making.
Main Methods
- Review of large population-based studies (Swedish and Japanese) examining associations between maternal drug use during pregnancy and offspring NDDs.
- Inclusion of sibling analyses to control for shared genetic and environmental factors.
- Comparison with other analgesic drug classes (aspirin, NSAIDs, opioids) and consideration of pain/inflammation as confounders.
Main Results
- Population studies show small associations (hazard ratios ~1.05-1.07) between prenatal acetaminophen and increased risks of ASD, ADHD, and intellectual disability (ID).
- Associations were also observed for aspirin, NSAIDs, and opioids with ASD/ADHD, but not ID.
- Crucially, sibling analyses found no association between gestational acetaminophen, aspirin, or other analgesics and NDD risk, suggesting shared familial factors are more likely responsible.
Conclusions
- The absolute risk increase for NDDs from gestational acetaminophen is minimal (e.g., 0.09% for ASD by age 10).
- Unmeasured confounding factors and shared genetic/environmental influences likely explain the observed associations, rather than acetaminophen itself.
- Acetaminophen remains a safer option than alternatives during pregnancy; restricting its use is unlikely to reduce NDD rates and requires shared decision-making with pregnant individuals.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...